Compare QTTB & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTTB | INCR |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.3M | 50.4M |
| IPO Year | 2018 | 2021 |
| Metric | QTTB | INCR |
|---|---|---|
| Price | $4.69 | $0.90 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 156.4K | 48.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $69.54 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 100.00 | N/A |
| 52 Week Low | $1.38 | $0.68 |
| 52 Week High | $6.37 | $1.77 |
| Indicator | QTTB | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.02 | 34.38 |
| Support Level | $3.99 | $0.76 |
| Resistance Level | $4.36 | $0.90 |
| Average True Range (ATR) | 0.40 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 62.50 | 36.01 |
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.